{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:15:23Z","timestamp":1790957723548,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"GUJCOST","award":["GUJCOST\/MRP\/14\u201315\/814"],"award-info":[{"award-number":["GUJCOST\/MRP\/14\u201315\/814"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.ejphar.2017.02.051","type":"journal-article","created":{"date-parts":[[2017,3,2]],"date-time":"2017-03-02T03:16:24Z","timestamp":1488424584000},"page":"28-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Molecular docking, synthesis and biological screening of mefenamic acid derivatives as anti-inflammatory agents"],"prefix":"10.1016","volume":"801","author":[{"given":"Jignasa K.","family":"Savjani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suja","family":"Mulamkattil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavesh","family":"Variya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snehal","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2017.02.051_bib1","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/pds.2011","article-title":"Risk of hyperkalemia associated with selective COX-2 inhibitors","volume":"19","author":"Aljadhey","year":"2010","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.ejphar.2017.02.051_bib2","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.ejmech.2012.01.018","article-title":"Synthesis, evaluation and docking studies on 3-alkoxy-4-methanesulfonamido acetophenone derivatives as non ulcerogenic anti-inflammatory agents","volume":"49","author":"Bali","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejphar.2017.02.051_bib3","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ejmech.2014.04.045","article-title":"Design and synthesis of novel 2-phenyl-5-(1,3-diphenyl-1H-pyrazol-4-yl)\u22121,3,4-oxadiazoles as selective COX-2 inhibitors with potent anti-inflammatory activity","volume":"80","author":"Bansal","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejphar.2017.02.051_bib4","first-page":"275","article-title":"The preliminary assessment of anti-microbial activity of Hplc separated components of <i>Kirkia Wilmsii<\/i> African J. Tradit. complement","volume":"11","author":"Chigayo","year":"2014","journal-title":"Altern. Med."},{"key":"10.1016\/j.ejphar.2017.02.051_bib5","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.2174\/0929867043365260","article-title":"New developments on thromboxane and prostacyclin modulators part I: thromboxane modulators","volume":"11","author":"Dogn\u00e9","year":"2004","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejphar.2017.02.051_bib6","doi-asserted-by":"crossref","first-page":"971","DOI":"10.2174\/138161206776055949","article-title":"Coxibs and cardiovascular side-effects: from light to shadow","volume":"12","author":"Dogn\u00e9","year":"2006","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejphar.2017.02.051_bib7","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/nrd1225","article-title":"COX-2 and beyond: approaches to prostaglandin inhibition in human disease","volume":"2","author":"FitzGerald","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2017.02.051_bib8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ejmech.2016.06.011","article-title":"Design, synthesis and biological evaluation of N-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)\u22121,3-diphenyl-1H-pyrazole-4-carboxamides as CDK1\/Cdc2 inhibitors","volume":"122","author":"Ganga Reddy","year":"2016","journal-title":"Eur. J. Med. Chem."},{"issue":"275","key":"10.1016\/j.ejphar.2017.02.051_bib9","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1126\/science.275.5297.218","article-title":"Cancer chemopreventive activity of resveratrol, a natural product derived from grapes","volume":"80-","author":"Jang","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2017.02.051_bib10","doi-asserted-by":"crossref","unstructured":"Kalgutkar, A.S., Crews, B.C., Rowlinson, S.W., Marnett, A.B., Kozak, K.R., Remmel, R.P., Marnett, L.J., 2000. Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proceedings Natl. Acad. Sci. U. S. A, 97, 925\u2013930.","DOI":"10.1073\/pnas.97.2.925"},{"key":"10.1016\/j.ejphar.2017.02.051_bib11","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0960-894X(01)00792-2","article-title":"Amide derivatives of meclofenamic acid as selective cyclooxygenase-2 inhibitors","volume":"12","author":"Kalgutkar","year":"2002","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejphar.2017.02.051_bib12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.15587\/2313-8416.2016.65209","article-title":"Synthesis of the row of new functional derivatives of 7-arylalkyl-8-hydrazine theophyllines","volume":"3","author":"Korobko","year":"2016","journal-title":"ScienceRise"},{"key":"10.1016\/j.ejphar.2017.02.051_bib13","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/art.10969","article-title":"Nonsteroidal antiinflammatory drugs and a selective cyclooxygenase 2 inhibitor uncouple mitochondria in intact cells","volume":"48","author":"Krause","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejphar.2017.02.051_bib14","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/j.1745-7254.2005.00151.x","article-title":"Design, synthesis, and anti-inflammatory evaluation of a series of novel amino acid-binding 1,5-diarylpyrazole derivatives","volume":"26","author":"Li","year":"2005","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejphar.2017.02.051_bib15","doi-asserted-by":"crossref","first-page":"22903","DOI":"10.1074\/jbc.274.33.22903","article-title":"Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition","volume":"274","author":"Marnett","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2017.02.051_bib16","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1161\/CIRCULATIONAHA.113.004480","article-title":"Nonsteroidal anti-inflammatory drugs and the heart","volume":"129","author":"Patrono","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2017.02.051_bib17","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1021\/jm960803q","article-title":"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)\u22123-(trifluoromethyl)\u22121H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib)","volume":"40","author":"Penning","year":"1997","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2017.02.051_bib18","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0960-894X(99)00288-7","article-title":"The discovery of rofecoxib, [MK 966, Vioxx, 4-(4\u2019-methylsulfonylphenyl)\u22123-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor","volume":"9","author":"Prasit","year":"1999","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejphar.2017.02.051_bib19","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S0022-3565(24)38776-2","article-title":"Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2","volume":"296","author":"Riendeau","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2017.02.051_bib20","first-page":"1336","article-title":"Drugs for rheumatic disease. Harold Paulus, Daniel Furst, and Sydney","volume":"31","author":"Roth","year":"1988"},{"key":"10.1016\/j.ejphar.2017.02.051_bib21","first-page":"284","volume":"56","author":"Smale","year":"2003","journal-title":"Determining small bowel Integr. Drug Treat. Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2017.02.051_bib22","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1248\/bpb.24.1133","article-title":"The effects of newly synthesized pyrazole derivatives on formaldehyde-, carrageenan-, and dextran-induced acute paw edema in rats","volume":"24","author":"S\u00fcleyman","year":"2001","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejphar.2017.02.051_bib23","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1021\/jm990577v","article-title":"4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, Valdecoxib: a potent and selective inhibitor of COX-2","volume":"43","author":"Talley","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2017.02.051_bib24","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.bmcl.2015.02.043","article-title":"Rapid \u201cone-pot\u201d synthesis of a novel benzimidazole-5-carboxylate and its hydrazone derivatives as potential anti-inflammatory and antimicrobial agents","volume":"25","author":"Vasantha","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejphar.2017.02.051_bib25","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S0960-894X(01)00212-8","article-title":"Thiazole analogues of the NSAID indomethacin as selective COX-2 inhibitors","volume":"11","author":"Woods","year":"2001","journal-title":"Bioorg. Med. Chem. Lett."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299917301383?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299917301383?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T22:42:17Z","timestamp":1750027337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299917301383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":25,"alternative-id":["S0014299917301383"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2017.02.051","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular docking, synthesis and biological screening of mefenamic acid derivatives as anti-inflammatory agents","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2017.02.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}